State Street Corp Boosts Stock Position in Assembly Biosciences Inc (NASDAQ:ASMB)

Share on StockTwits

State Street Corp boosted its holdings in Assembly Biosciences Inc (NASDAQ:ASMB) by 18.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 551,324 shares of the biopharmaceutical company’s stock after purchasing an additional 85,622 shares during the period. State Street Corp’s holdings in Assembly Biosciences were worth $8,176,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its position in shares of Assembly Biosciences by 188.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 8,620 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 5,633 shares during the last quarter. Morgan Stanley lifted its position in shares of Assembly Biosciences by 169.2% during the 1st quarter. Morgan Stanley now owns 160,050 shares of the biopharmaceutical company’s stock valued at $2,374,000 after buying an additional 100,586 shares during the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Assembly Biosciences during the 1st quarter valued at $266,000. Geode Capital Management LLC lifted its position in shares of Assembly Biosciences by 21.8% during the 1st quarter. Geode Capital Management LLC now owns 413,809 shares of the biopharmaceutical company’s stock valued at $6,136,000 after buying an additional 74,163 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Assembly Biosciences during the 1st quarter worth about $175,000. 88.31% of the stock is currently owned by institutional investors and hedge funds.

ASMB opened at $22.20 on Friday. The stock’s 50 day simple moving average is $23.02 and its 200 day simple moving average is $19.38. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.14 and a quick ratio of 12.14. Assembly Biosciences Inc has a 1 year low of $8.13 and a 1 year high of $27.84. The firm has a market cap of $726.38 million, a price-to-earnings ratio of -6.47 and a beta of 1.32.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.22. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%. The business had revenue of $4.08 million for the quarter, compared to analyst estimates of $3.82 million. As a group, sell-side analysts anticipate that Assembly Biosciences Inc will post -2.05 EPS for the current year.

A number of brokerages recently issued reports on ASMB. BidaskClub cut Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Zacks Investment Research lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 23rd. ValuEngine lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. William Blair reiterated a “buy” rating on shares of Assembly Biosciences in a research report on Thursday, June 25th. Finally, Mizuho reiterated a “buy” rating and set a $30.00 price objective on shares of Assembly Biosciences in a research report on Friday, May 8th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $39.40.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Read More: Bond

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cambridge Investment Research Advisors Inc. Purchases 13,393 Shares of Fifth Third Bancorp
Cambridge Investment Research Advisors Inc. Purchases 13,393 Shares of Fifth Third Bancorp
Pinterest  PT Raised to $31.00 at Credit Suisse Group
Pinterest PT Raised to $31.00 at Credit Suisse Group
Fifth Third Bancorp  Shares Sold by Strs Ohio
Fifth Third Bancorp Shares Sold by Strs Ohio
Cambridge Investment Research Advisors Inc. Purchases 14,372 Shares of XPO Logistics Inc
Cambridge Investment Research Advisors Inc. Purchases 14,372 Shares of XPO Logistics Inc
Sumitomo Mitsui Trust Holdings Inc. Lowers Stock Position in Main Street Capital Co.
Sumitomo Mitsui Trust Holdings Inc. Lowers Stock Position in Main Street Capital Co.
Microsoft Co.  is Palisade Asset Management LLC’s Largest Position
Microsoft Co. is Palisade Asset Management LLC’s Largest Position


© 2006-2020 Ticker Report